Scarica l'app Stockscreener
13.84
13.33%
-2.14
Regenxbio Inc Borsa (RGNX) Ultime notizie
Gene Therapy Market Outlook 2026-2031, Featuring Profiles - GlobeNewswire
REGENXBIO (NASDAQ:RGNX) Sets New 12-Month HighWhat's Next? - MarketBeat
Wet Age-Related Macular Degeneration Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Opthea Limited, Regenxbio, Alkahest, Graybug Vision, Alcon Research, Qilu - Barchart.com
REGENXBIO Inc. (RGNX): A Bull Case Theory - Insider Monkey
Aug Sectors: Is REGENXBIO Inc stock a good dividend stockWatch List & Weekly Breakout Watchlists - baoquankhu1.vn
Aug Catalysts: Why is REGENXBIO Inc stock going upSwing Trade & Stepwise Trade Signal Guides - baoquankhu1.vn
Street Watch: Is REGENXBIO Inc impacted by rising ratesQuarterly Portfolio Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Regenxbio Shares Retreat as Market Digests Conflicting Signals - AD HOC NEWS
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
REGENXBIO (NASDAQ:RGNX) Stock Price Down 6.7%What's Next? - MarketBeat
Patients Treated With REGENXBIO’s DMD Gene Therapy RGX-202 Exceed Expected Disease Trajectory on NSAA - Neurology Live
Is REGENXBIO Inc in a long term uptrendPrice Action & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
RGNX: Pivotal data and regulatory milestones in Duchenne, wet AMD, and Hunter programs drive a transformative year - TradingView — Track All Markets
RGNX: Late-stage gene therapy programs show strong efficacy, safety, and commercial readiness for 2024 - TradingView — Track All Markets
$191.2 Million Achromatopsia Market Outlook, 2026-2032, - GlobeNewswire
$191.2 Million Achromatopsia Market Outlook, 2026-2032, Featuring Adverum Biotechnologies, Homology Medicines, Mattel, REGENXBIO, Sanofi and More - Yahoo Finance
Is REGENXBIO Inc stock undervalued right nowJuly 2025 Highlights & Technical Pattern Based Buy Signals - baoquankhu1.vn
Technical Reactions to RGNX Trends in Macro Strategies - Stock Traders Daily
Macular Degeneration Treatment Market is expected to reach US$ - openPR.com
Hedge Fund Moves: What hedge fund activity signals for REGENXBIO Inc. stockMarket Sentiment Review & Fast Exit and Entry Trade Guides - Bộ Nội Vụ
Lobbying Update: $60,000 of REGENXBIO INC. lobbying was just disclosed - Quiver Quantitative
Market Overview: Is REGENXBIO Inc stock undervalued right now2025 Price Action Summary & Fast Gain Swing Alerts - baoquankhu1.vn
REGENXBIO (NASDAQ:RGNX) Shares Gap UpShould You Buy? - MarketBeat
Regenxbio (RGNX) Shares Rise on Promising Duchenne Therapy Data - GuruFocus
Regenxbio stock maintains Buy rating at H.C. Wainwright on positive DMD trial data - Investing.com Australia
REGENXBIO Stock Hits New High On Duchenne Trial DataWill 2026 Be A Transformative Year? - RTTNews
Regenxbio stock rating reiterated at Outperform by Baird on positive RGX-202 data - Investing.com South Africa
REGENXBIO (RGNX) Advances Gene Therapy Pipeline for Future Miles - GuruFocus
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program - Chartmill
Aug PostEarnings: How REGENXBIO Inc stock performs during Fed tightening cycles2025 Major Catalysts & Smart Investment Allocation Tips - moha.gov.vn
REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a 107% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Why REGENXBIO Inc. stock is trending among retail traders2025 Volume Leaders & Safe Capital Growth Stock Tips - Улправда
What hedge fund activity signals for REGENXBIO Inc. stockMarket Performance Report & Safe Swing Trade Setup Alerts - Улправда
Why REGENXBIO Inc. stock is recommended by analystsPortfolio Gains Report & Growth Focused Entry Reports - ulpravda.ru
How REGENXBIO Inc. stock trades during market volatilityJuly 2025 Levels & Daily Chart Pattern Signal Reports - Улправда
Is REGENXBIO Inc. stock gaining market share2025 Institutional Moves & Low Risk High Reward Ideas - ulpravda.ru
How REGENXBIO Inc. stock benefits from global expansionDividend Stock Watch & Start Your Free Trading Journey Today - ulpravda.ru
REGENXBIO (NASDAQ:RGNX) Sets New 1-Year HighStill a Buy? - MarketBeat
RegenXBio (RGNX) Gets a Buy from Bank of America Securities - The Globe and Mail
BofA Securities Raises Price Target on REGENXBIO to $28 From $20, Maintains Buy Rating - marketscreener.com
RegenXBio’s RGX-202: Promising Long-term Study for Duchenne Muscular Dystrophy - MSN
REGENXBIO updates Phase 1/2 data for Duchenne candidate - msn.com
Trading the Move, Not the Narrative: (RGNX) Edition - Stock Traders Daily
Prospects for Regenxbio’s clemidsogene lanparvovec approval in Hunter syndrome - The Pharma Letter
REGENXBIO (NASDAQ:RGNX) Trading Down 3.8%Here's Why - MarketBeat
Regenxbio (RGNX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Behavioral Patterns of RGNX and Institutional Flows - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Hits New 1-Year HighWhat's Next? - MarketBeat
Assenagon Asset Management S.A. Purchases 132,942 Shares of REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Stifel raises Regenxbio stock price target to $45 on upcoming catalysts By Investing.com - Investing.com Australia
Stifel Maintains REGENXBIO (RGNX) Buy Recommendation - Nasdaq
3.19%
2.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):